Skip to main content
Clinical Trials/NCT05023538
NCT05023538Active, not recruitingNot Applicable

PROTECTION Study: PReventiOn of HearT Failure in Type 2 Diabetes by ExerCise InTerventION

Hasselt University4 sites in 1 country182 target enrollmentStarted: March 1, 2022Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Active, not recruiting
Sponsor
Enrollment
182
Locations
4
Primary Endpoint
mPAP/CO and mPAP/CO slope

Study Overview

Brief Summary

Global longitudinal strain emerged as an important predictive marker that could be assessed during echocardiography. It enabled the detection of subclinical myocardial systolic dysfunction, without observable reductions in cardiac output or left ventricular ejection fraction, often years before diabetes induced heart failure. In asymptomatic T2D patients with no history of cardiovascular disease, an impaired global longitudinal strain is a predictor of future adverse left ventricular remodeling and adverse cardiovascular events. Exercise training is a promising intervention to interfere in the diabetes induced heart failure pathophysiology. However, the impact of different exercise modalities (e.g. intensity and volume) on the global longitudinal strain in type 2 diabetes (T2D) is unknown.

Detailed Description

More than 400 million people worldwide are affected by diabetes mellitus whose prevalence keeps increasing. In type 2 diabetes mellitus (T2DM), up to 23% of the patients have asymptomatic diastolic and 13% systolic cardiac dysfunction. Diabetes-induced heart failure (DIHF), with reduced or preserved ejection fraction, is thus one of the major complications of T2DM, which is characterized by structural and functional changes in the myocardium in absence of coronary artery disease, other cardiac pathologies or hypertension. These changes significantly affect prognosis: patients with DIHF are at a 147% elevated risk for premature death within 4 years vs. 29% in patients without DIHF. It is thus of the utmost importance to prevent the development of DIHF. Although the exact mechanisms are not fully understood, hyperglycemia, hyperinsulinemia and hyperlipidemia are considered as key risk factors, but also oxidative and dicarbonyl stress, advanced glycation end products (AGEs) and inflammation play an important role in the pathophysiology of DIHF.

To prevent adverse cardiac remodeling in T2DM and the development of DIHF, early biomarkers are mandatory. In this respect, in the past few years global longitudinal strain (GLS) emerged as an important predictive marker that could be assessed during echocardiography: the global longitudinal strain enables the detection of subclinical myocardial systolic dysfunction, without observable reductions in cardiac output or left ventricular ejection fraction, often years before DIHF. In asymptomatic T2DM patients with no history of cardiovascular disease, an impaired GLS is a predictor of future adverse left ventricular (LV) remodeling and adverse cardiovascular events, thus providing incremental prognostic value beyond clinical data, glycated hemoglobin (HbA1c) and diastolic function. The investigators found that GLS is indeed significantly lowered (by ±14%, at rest and during low-intense and high-intense exercise, in asymptomatic well-controlled T2DM patients (HbA1c: 6.9±0.7%). During exercise, GLS increases in T2DM, but fails to normalize when compared with healthy controls. In contrast to current assumption, the investigators' data demonstrate that a disturbed GLS is highly common in T2DM patients.

Exercise training is strongly recommended to T2DM patients, and is a crucial treatment next to medication and diet, as this (further) optimizes glycemic control by improving insulin sensitivity, next to the positive impact on physical fitness, blood pressure, lipid profile and body composition. Recent evidence also indicates a significantly lowered mortality in habitual physically active vs. non-active T2DM patients (hazard ratio=0.61).

What type of exercise is most effective? What remains debatable is whether exercise intervention can prevent the development of DIHF in asymptomatic T2DM patients. According to a recent systematic review from the investigators' laboratory, the impact of exercise intervention on GLS in asymptomatic T2DM is equivocal: significant improvements from some studies could not be reproduced in other. In line with these findings, the investigators' unpublished pilot data also reveal the capability of exercise training to improve GLS in some T2DM patients.

The investigators' data show the potency of exercise in preventing DIHF in asymptomatic T2DM patients, but they also show that crucial aspects deserve further study to maximize the benefits of exercise training on GLS in T2DM patients, and hereby to offer maximal protection against the development of DIHF.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Prevention
Masking
Double (Investigator, Outcomes Assessor)

Masking Description

Researchers performing the outcome assessments and analyses will be blinded to treatment.

Eligibility Criteria

Ages
30 Years to 75 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • physically inactive (no participation in structured or unstructured physical activity (PA) and not reaching the recommended PA guidelines: initially based on the International Physical Activity Questionnaire )
  • age between 30-75 years
  • blood HbA1c of 6-10% (if taking blood glucose lowering medication) or 6.5-10% without taking blood glucose lowering medication, and/or two-hour plasma glucose ≥11.1 mmol/L or ≥200 mg/dL following a 75g oral glucose load during OGTT.
  • women of child bearing age will be included into the trial.

Exclusion Criteria

  • exogenous insulin therapy
  • individuals suffering from any disease with significant impact on exercise intervention participation, such as: chronic heart disease or significant arrhythmias, cardiac events (myocardial infarction, coronary artery bypass graft, percutaneous coronary intervention), chronic obstructive pulmonary, cerebrovascular or peripheral vascular disease, severe hypertension (>160/110 mmHg), cancer, severe neuropathy (limiting exercise participation).

Outcomes

Primary Outcomes

mPAP/CO and mPAP/CO slope

Time Frame: at baseline and 6 months

* Mean pulmonary artery pressure by cardiac output and by cardiac output slope * mPAP/CO slope will be calculated via measurement of LVOTdiameter, LVOT VTI and sPAP at three timepoints during exercise echocardiography. These timepoints are: rest, low intense exercise (HR\<100 before fusion of early and late mitral inflow (E \& A)), and high-intense exercise (RER 1.02-1.05).

Global longitudinal strain (%)

Time Frame: at baseline and 6 months

Cardiac function evaluation by echocardiography at rest

Secondary Outcomes

  • Fasted Blood draw(baseline, 3m and 6m)
  • Cardiopulmonary exercise testing on a bicycle(baseline, 3m and 6m)
  • Physical activity via Actigraph wGT3X-BT(baseline, 3 and 6 months)
  • Body composition (%fat) via bioelectrical impedance(baseline, 3 and 6m)
  • Rest and exercise echocardiography(baseline and 6m)

Investigators

Sponsor
Hasselt University
Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Dominique Hansen

Professor

Hasselt University

Study Sites (4)

Loading locations...

Similar Trials

Prevention of Heart Failure in Type 2... | Clinical Trial